Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens

被引：0
|
作者：
Lim, Sung Won
Park, Song Ee
Cho, Jangho
Kim, Youjin
Lee, Hansang
Hong, Juhyun
Jeon, Eunseok
Choi, Jinoh
Lee, Gayeon
Kim, Byungjun
Min, Ju Hong
Kim, Jung Sun
Lee, Jung Eun
Choi, Joon Young
Park, Silvia
Kim, Seok Jin
Jang, Jun Ho
Kim, Won Seog
Jung, Chul Won
Kim, Kihyun
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3114
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens
    Roussou, Maria
    Kastritis, Efstathios
    Migkou, Magdalini
    Psimenou, Erasmia
    Grapsa, Irini
    Matsouka, Charis
    Barmparousi, Despina
    Terpos, Evangelos
    Dimopoulos, Meletios Athanasios
    LEUKEMIA & LYMPHOMA, 2008, 49 (05) : 890 - 895
  • [32] Bortezomib-Based Chemotherapy Regimens Can Inmprove The Complete Remission In Newly Diagnosed Multiple Myeloma Patients With Bcl-2 and Survivin Overexpression
    Wen, Zeng
    Huang Lifang
    Zhang, Yicheng
    Sun Hanying
    Liu Wenli
    Meng Fankai
    Zhou Jianfeng
    BLOOD, 2013, 122 (21)
  • [33] CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens
    Xiao-Ying Qin
    Jin Lu
    Guo-Xuan Li
    Lei Wen
    Yang Liu
    Lan-Ping Xu
    Ying-Jun Chang
    Kai-Yan Liu
    Zheng-Fan Jiang
    Xiao-Jun Huang
    Annals of Hematology, 2018, 97 : 485 - 495
  • [34] Polymorphisms of CTLA-4 Are Associated with Treatment Outcome in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens
    Qin, Xiao-Ying
    Lu, Jin
    Li, Guo-Xuan
    Wen, Lei
    Xu, Lan-Ping
    Chang, Ying-Jun
    Liu, Kai-Yan
    Jiang, Zheng-Fan
    Huang, Xiao-Jun
    BLOOD, 2016, 128 (22)
  • [35] Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
    He, Jingsong
    He, Donghua
    Han, Xiaoyan
    Zheng, Gaofeng
    Wei, Guoqing
    Zhao, Yi
    Yang, Yang
    Wu, Wenjun
    Fu, Jiaping
    Shou, Lihong
    Kong, Hongwei
    Huang, He
    Cai, Zhen
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [36] The effect of bortezomib monotherapy and bortezomib-based regimens on bone metabolism in patients with relapsed/refractory multiple myeloma
    Terpos, E.
    Heath, D. J.
    Zervas, K.
    Anagnostopoulos, A.
    Katodritou, E.
    Christoulas, D.
    Pouli, A.
    Chantry, A.
    Anargyrou, K.
    Kastritis, E.
    Verrou, E.
    Tsionos, K.
    Croucher, P.
    Dimopoulus, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 133 - 134
  • [37] Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma
    Lamm, W.
    Drach-Schauer, B.
    Eder, S.
    Drach, J.
    ONCOLOGY, 2013, 85 (04) : 223 - 227
  • [38] Bortezomib-based regimens for primary multiple myeloma patients in China: from 2006 to 2018
    Cai, Zhen
    He, Jingsong
    He, Donghua
    Han, Xiaoyan
    Zheng, Gaofeng
    Zhao, Yi
    Yang, Yang
    Wu, Wenjun
    Huang, He
    Fu, Jiaping
    Shou, Lihong
    Kong, Hongwei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E202 - E202
  • [39] Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving bortezomib-based therapy for multiple myeloma
    Zhou, Xin
    Wang, Jing
    Xia, Jun
    Cheng, Feng
    Mao, Jingjue
    Zhu, Jianwei
    Guo, Hongfeng
    CANCER BIOMARKERS, 2018, 22 (01) : 43 - 48
  • [40] Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
    Wang, Hua
    Wang, Liang
    Lu, Yue
    Chen, Xiaoqin
    Geng, Qirong
    Wang, Weida
    Xia, Zhongjun
    ONCOTARGETS AND THERAPY, 2016, 9 : 587 - 595
12345